Shionogi & Co. looks set to put its COVID-19 vaccine into practical use by the end of March 2022 following a government decision to change clinical trial methods that put Japanese vaccine developers ...
Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’ MZE001, an oral glycogen synthase 1 (GYS1) inhibitor to treat Pompe disease. The agreement grants Shionogi the sole ...
Shionogi Inc., a United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will share17 scientific presentations from across its ...
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a pharmaceutical company with a significant focus on infectious diseases, announced today the expanded leadership roles of executive vice president ...
Shionogi are able to secure a continued revenue stream from the integrase inhibitor portfolio as well as a stake in ViiV Healthcare itself, and will be able to contribute to the future direction of ...
Shionogi & Co. will partner with Sage Therapeutics to develop and commercialize Sage’s SAGE-217 to treat major depressive disorder (MDD) and other indications in Japan, Taiwan, and South Korea, ...
London, UK, 21 July 2010 - Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 (‘572) into Phase III ...
For most drugmakers, it pays to focus on high-priced drugs in new treatment areas. But Japan’s Shionogi is counting on the opposite. Shionogi CEO Isao Teshirogi told Bloomberg that the company, which ...
ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegravir Shionogi receives ongoing royalty and dividend stream and receives 10% equity in ViiV ...
CORK, IRELAND--(Marketwired - Apr 9, 2013) - QUMAS today announced that Shionogi & Co., Ltd., a leading Japanese pharmaceutical company, has selected QUMAS ComplianceSP™ software to manage its quality ...
TOKYO -- Japanese drugmakers Shionogi and Daiichi Sankyo look to ensure that their vaccines under development will be effective against the new omicron variant of the coronavirus. Shionogi is ...
Japanese Prime Minister Fumio Kishida on Monday said the government would consider fast tracking the approval of a new antiviral pill to treat Covid-19 developed by Shionogi after the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback